Form 8-K
8-K — Scribe Therapeutics, Inc.
Accession: 0001193125-26-458486
Filed: 2026-11-12
Period: 2026-11-12
CIK: 0001853921
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — sctx-20261112.htm (Primary)
EX-99.1 (sctx-ex99_1.htm)
GRAPHIC (img260493329_0.gif)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: sctx-20261112.htm · Sequence: 1
8-K
false000185392100018539212026-11-122026-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
Scribe Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-43409
82-2157847
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
1150 Marina Village Parkway
Alameda, California
94501
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 510 626-8587
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common stock, $0.001 par value per share
SCTX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026 and provided a business update. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit number
Description
99.1
Earnings Press Release Issued by Scribe Therapeutics Inc on November 12, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12, 2026
By:
/s/ Benjamin L. Oakes
Benjamin L. Oakes, Ph.D.
Chief Executive Officer
(Principal Executive Officer)
EX-99.1
EX-99.1
Filename: sctx-ex99_1.htm · Sequence: 2
EX-99.1
Scribe Therapeutics Reports Third Quarter 2026 Financial Results
and Recent Corporate Highlights
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400
Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027
Expanded strategic collaboration with Sanofi, providing access to the Company’s ELXR silencing technology and further validating its platform innovation
Reinforced leadership in genetic medicines through presentations and a new publication highlighting advances across the Company’s cardiovascular pipeline and proprietary epigenetic silencing and gene-editing technologies
Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029
ALAMEDA, Calif., November 12, 2026 – Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate and pipeline updates.
During the third quarter, Scribe continued to build on the momentum generated by its successful initial public offering. The Company completed an upsized IPO, welcomed leading public healthcare investors to its shareholder base, and broadened analyst coverage, positioning the Company to execute against its long-term vision of developing durable genetic medicines for highly prevalent cardiometabolic diseases.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics.
Pipeline Highlights
STX-1150: In vivo epigenetic silencing therapy for low-density lipoprotein cholesterol (LDL-C) lowering in ongoing Phase 1 clinical trial
•
STX-1150 utilizes Scribe’s Epigenetic Long-term X Repressor (ELXR) technology to silence PCSK9, a genetically and clinically validated target for LDL-C lowering.
•
STX-1150 is designed to address a major limitation of current LDL-C lowering approaches and is positioned to recapitulate the cardioprotective effects of human genetics.
•
Current LDL-C lowering therapies are limited by poor persistence and adherence, with studies showing that 50% to 70% of patients discontinue treatment within one year.
•
STX-1150 is designed to overcome these challenges by providing potent, ultra-long-lasting LDL-C reduction.
•
STX-1150 aims to mimic the protective cardiovascular profile observed in individuals with naturally occurring PCSK9 loss-of-function variants, who have been reported to have 28% lower mean LDL-C levels and up to 88% lower coronary heart disease risk. By recapitulating the effects of this naturally occurring protection, STX-1150 has the potential to shift LDL-C management from burdensome chronic treatment to long-term prevention.
•
Presented late-breaking data at the American Heart Association (AHA) Scientific Sessions 2026 meeting supporting STX-1150 for ultra-long-lasting LDL-C lowering after a single dose without permanently altering DNA.
•
A single administration at a therapeutically relevant dose of 0.75 mg/kg demonstrated durable LDL-C reductions of greater than 50%, sustained for two years, with liver enzyme profiles comparable to saline controls in non-human primates (NHP).
•
In an additional NHP study, re-dosing of STX-1150 enabled progressively greater LDL-C lowering while maintaining tolerability.
•
First-in-human Phase 1 clinical trial of STX-1150, initiated in mid-2026, is ongoing. Clinical data expected in the first half of 2027.
•
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of STX-1150 in adults with elevated low-density lipoprotein cholesterol and increased risk of atherosclerotic cardiovascular disease (ASCVD).
•
Scribe anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose portion of the STX-1150 Phase 1 trial in the first half of 2027.
STX-1200: In vivo gene editing designed to provide curative lowering for patients with genetically elevated Lp(a)
•
Presented data at the AHA Scientific Sessions 2026 meeting highlighting STX-1200, which targets LPA utilizing X-Editor (XE), Scribe’s highly engineered gene editing technology.
•
STX-1200 is designed to lower lipoprotein(a) (Lp(a)) in patients with genetically elevated Lp(a) and associated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHPs.
Corporate Highlights
•
Nasdaq listing: The Company’s common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial public offering and priced at the high end of the range. The Company also completed a concurrent private placement to Sanofi at the IPO price.
•
Approximately $155.5 million in aggregate gross proceeds: Capital raised from the IPO, the full exercise of the underwriters’ option, and the concurrent private placement totaled $155.5 million before underwriting discounts, commissions, and offering expenses.
•
Funding into the first half of 2029: Based on Scribe’s current operating plan, the Company believes its cash, cash equivalents, and marketable securities will be sufficient to fund its
operating expenses and capital expenditure requirements into the first half of 2029.
•
Expanded strategic collaboration with Sanofi to include Scribe’s ELXR epigenetic silencing technology: Scribe expanded its multi-year research collaboration with Sanofi, providing Sanofi access to Scribe’s proprietary ELXR epigenetic silencing technology in addition to its XE gene-editing technology and extending Sanofi’s nomination period for target selection under the license agreement.
Platform and Scientific Leadership
•
Presented advances in ELXR epigenetic silencing technology demonstrating improvements in potency and specificity.
•
At the European Society of Gene and Cell Therapy (ESGCT) Congress, Scribe presented findings demonstrating a novel approach to epigenetic silencing termed “sequential proofreading” that reduces unintended DNA methylation by 10-fold and enhances potency by at least 4-fold.
•
These advances highlight ELXR’s differentiated potency and precision and underpin the Company's lead asset STX-1150, currently in the clinic for LDL-C lowering.
•
New data highlight advances in industry-leading genome editing potency and specificity of the Company’s engineered XE gene-editing technology.
•
The Company’s comprehensive and iterative molecular engineering approach transformed CRISPR-CasX, a naturally occurring bacterial immune system, into its highly engineered XE gene-editing technology for therapeutic development. This foundational work underpins the Company’s STX-1200 and STX-1400 programs and has contributed to the development of its clinical-stage STX-1150 program, demonstrating the broader applicability of Scribe’s engineered platforms for cardiovascular disease.
•
The engineered XE technology exhibited >100-fold improvements in editing activity compared with naturally occurring CasX and demonstrated its ability to potently edit genes in vivo across muscle, eye, liver, and brain tissue.
•
XE demonstrated the potential for a broader therapeutic window by achieving saturating editing across two distinct genomic targets in NHP liver, with no detectable off-target editing in primary human liver cells at 10-fold supersaturating doses.
•
These findings demonstrate that XE is more potent at lower doses than comparable preclinical data from Cas9-based therapies that are now in clinical testing.
•
A manuscript has been submitted to bioRxiv and will be available in the Publications section of the Company’s website once posted.
Third Quarter 2026 Financial Results
•
Cash position: Cash, cash equivalents, and marketable securities were $174.2 million as of September 30, 2026, compared to $43.0 million as of June 30, 2026. The increase was primarily driven by approximately $140.2 million of net proceeds from the July 2026 IPO and concurrent private placement, partially offset by cash used in operations. Cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to provide funding into the first half of 2029.
•
Collaboration revenue: For the three months ended September 30, 2026, collaboration revenue totaled $1.6 million, compared to $1.9 million for the three months ended June 30, 2026. The decrease was primarily attributable to lower revenue recognized under the Eli Lilly collaboration due to lower reimbursable research and development activities incurred in the period.
•
Research and development expenses: For the three months ended September 30, 2026, research and development expenses totaled $8.3 million, compared to $8.8 million for the three months ended June 30, 2026. The decrease was primarily attributable to lower employee-related and external research and development expenses and the recognition of grant funding from the California Institute for Regenerative Medicine (CIRM) as an offset to research and development expenses.
•
General and administrative expenses: For the three months ended September 30, 2026, general and administrative expenses totaled $4.2 million, compared to $2.5 million for the three months ended June 30, 2026. The increase was primarily attributable to higher stock-based compensation expenseand increased professional services fees and other costs associated with operating as a public company.
•
Net loss: For the three months ended September 30, 2026, net loss was $9.9 million, or $0.68 per basic and diluted share, compared to a net loss of $6.5 million for the three months ended June 30, 2026.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, STX-1400 and other programs; the expected use and benefits of CIRM funding; and Scribe’s expected cash runway and financial position are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to
update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
SCRIBE THERAPEUTICS INC.
Statement of Operations
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Collaboration revenue
$
1,636
$
20,113
$
5,787
$
42,136
Operating expenses:
Research and development
8,259
14,421
28,386
44,297
General and administrative
4,239
3,531
10,084
12,863
Total operating expenses
12,498
17,952
38,470
57,160
Loss from operations
(10,862
)
2,161
(32,683
)
(15,024
)
Interest income and other income, net
1,230
772
2,128
2,716
Interest expense
—
(598
)
(875
)
(1,795
)
Change in fair value of Convertible Note
—
(539
)
(1,585
)
1,543
Net loss before provision for income taxes
(9,632
)
1,796
(33,015
)
(12,560
)
(Provision for) / benefit from income tax
(231
)
(324
)
(672
)
703
Net loss
$
(9,863
)
$
1,472
$
(33,687
)
$
(11,857
)
SCRIBE THERAPEUTICS INC.
Selected Balance Sheet Items
(in thousands, except share and per share data)
(Unaudited)
September 30,
December 31,
2026
2025
(in thousands)
Cash, cash equivalents and investments
$
174,230
$
57,963
Total Assets
187,930
78,219
Total Liabilities
62,760
101,282
Total stockholders' equity / (deficit)
$
125,170
$
(143,419
)
GRAPHIC
GRAPHIC
Filename: img260493329_0.gif · Sequence: 3
Binary file (26177 bytes)
Download img260493329_0.gif
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 6
v3.26.3
Document And Entity Information
Nov. 12, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Nov. 12, 2026
Entity Registrant Name
Scribe Therapeutics, Inc.
Entity Central Index Key
0001853921
Entity Emerging Growth Company
true
Entity File Number
001-43409
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
82-2157847
Entity Address, Address Line One
1150 Marina Village Parkway
Entity Address, City or Town
Alameda
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
94501
City Area Code
510
Local Phone Number
626-8587
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Ex Transition Period
false
Title of 12(b) Security
Common stock, $0.001 par value per share
Trading Symbol
SCTX
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration